Pathway | n | r | z | Calcium Regulation in the Cardiac Cell | 136 | 136 | NaN |
Urea cycle and metabolism of amino groups | 19 | 19 | NaN |
GPCRs, Other | 59 | 59 | NaN |
Glutathione metabolism | 17 | 17 | NaN |
Gene regulatory network modelling somitogenesis | 9 | 9 | NaN |
Hypothetical Network for Drug Addiction | 31 | 31 | NaN |
TGF Beta Signaling Pathway | 52 | 52 | NaN |
Alzheimers Disease | 77 | 77 | NaN |
Regulation of toll-like receptor signaling pathway | 119 | 119 | NaN |
Constitutive Androstane Receptor Pathway | 25 | 25 | NaN |
Secretion of Hydrochloric Acid in Parietal Cells | 2 | 2 | NaN |
Trans-sulfuration pathway | 10 | 10 | NaN |
mRNA Processing | 125 | 125 | NaN |
Pentose Phosphate Pathway | 7 | 7 | NaN |
Focal Adhesion | 184 | 184 | NaN |
p38 MAPK Signaling Pathway | 34 | 34 | NaN |
TCA Cycle and PDHc | 16 | 16 | NaN |
Bladder Cancer | 30 | 30 | NaN |
Oxidative phosphorylation | 51 | 51 | NaN |
Cell Differentiation - Index | 10 | 10 | NaN |
Parkin-Ubiquitin Proteasomal System pathway | 67 | 67 | NaN |
Cori Cycle | 12 | 12 | NaN |
Hypoxia-mediated EMT and Stemness | 2 | 2 | NaN |
Osteoblast Signaling | 11 | 11 | NaN |
Fluoropyrimidine Activity | 31 | 31 | NaN |
TSLP Signaling Pathway | 45 | 45 | NaN |
Oxidation by Cytochrome P450 | 48 | 48 | NaN |
Integrated Pancreatic Cancer Pathway | 192 | 192 | NaN |
TWEAK Signaling Pathway | 42 | 42 | NaN |
Globo Sphingolipid Metabolism | 22 | 22 | NaN |
Complement and Coagulation Cascades | 47 | 47 | NaN |
Semaphorin interactions | 61 | 61 | NaN |
Diurnally Regulated Genes with Circadian Orthologs | 46 | 46 | NaN |
Interactome of polycomb repressive complex 2 (PRC2) | 16 | 16 | NaN |
Folate Metabolism | 50 | 50 | NaN |
Membrane Trafficking | 76 | 76 | NaN |
Statin Pathway | 22 | 22 | NaN |
Interferon type I signaling pathways | 54 | 54 | NaN |
PDGF Pathway | 38 | 38 | NaN |
AGE/RAGE pathway | 62 | 62 | NaN |
Alanine and aspartate metabolism | 10 | 10 | NaN |
Myometrial Relaxation and Contraction Pathways | 146 | 146 | NaN |
Cardiac Progenitor Differentiation | 46 | 46 | NaN |
ErbB Signaling Pathway | 52 | 52 | NaN |
Mitochondrial LC-Fatty Acid Beta-Oxidation | 17 | 17 | NaN |
Complement Activation, Classical Pathway | 10 | 10 | NaN |
AMPK Signaling | 64 | 64 | NaN |
Catalytic cycle of mammalian FMOs | 4 | 4 | NaN |
TFs Regulate miRNAs related to cardiac hypertrophy | 8 | 8 | NaN |
DDX1 as a regulatory component of the Drosha microprocessor | 7 | 7 | NaN |
Hair Follicle Development: Induction (Part 1 of 3) | 42 | 42 | NaN |
Blood Clotting Cascade | 13 | 13 | NaN |
IL1 and megakaryotyces in obesity | 20 | 20 | NaN |
FSH signaling pathway | 23 | 23 | NaN |
Synaptic Vesicle Pathway | 44 | 44 | NaN |
T-Cell Receptor and Co-stimulatory Signaling | 26 | 26 | NaN |
Tamoxifen metabolism | 15 | 15 | NaN |
Integrated Cancer pathway | 44 | 44 | NaN |
Amino acid conjugation of benzoic acid | 3 | 3 | NaN |
Heart Development | 41 | 41 | NaN |
Angiogenesis | 24 | 24 | NaN |
Serotonin Transporter Activity | 11 | 11 | NaN |
Codeine and Morphine Metabolism | 8 | 8 | NaN |
Methylation Pathways | 7 | 7 | NaN |
mir34a and TGIF2 in osteoclastogenesis | 1 | 1 | NaN |
Extracellular vesicle-mediated signaling in recipient cells | 29 | 29 | NaN |
Deregulation of Rab and Rab Effector Genes in Bladder Cancer | 16 | 16 | NaN |
Parkinsons Disease Pathway | 39 | 39 | NaN |
Spinal Cord Injury | 100 | 100 | NaN |
Eukaryotic Transcription Initiation | 41 | 41 | NaN |
Nucleotide GPCRs | 9 | 9 | NaN |
Vitamin B12 Metabolism | 37 | 37 | NaN |
Wnt Signaling Pathway and Pluripotency | 96 | 96 | NaN |
Adipogenesis | 120 | 120 | NaN |
Nicotine Metabolism | 2 | 2 | NaN |
Small Ligand GPCRs | 13 | 13 | NaN |
Arrhythmogenic Right Ventricular Cardiomyopathy | 64 | 64 | NaN |
EPO Receptor Signaling | 25 | 25 | NaN |
RalA downstream regulated genes | 12 | 12 | NaN |
EGF/EGFR Signaling Pathway | 159 | 159 | NaN |
Selenium Micronutrient Network | 63 | 63 | NaN |
EBV LMP1 signaling | 22 | 22 | NaN |
Differentiation Pathway | 44 | 44 | NaN |
Glucose Homeostasis | 0 | 0 | NaN |
TSH signaling pathway | 64 | 64 | NaN |
Insulin Signaling | 158 | 158 | NaN |
Wnt Signaling Pathway | 62 | 62 | NaN |
G1 to S cell cycle control | 66 | 66 | NaN |
IL17 signaling pathway | 26 | 26 | NaN |
Monoamine GPCRs | 23 | 23 | NaN |
IL-1 signaling pathway | 55 | 55 | NaN |
B Cell Receptor Signaling Pathway | 94 | 94 | NaN |
RNA interference | 5 | 5 | NaN |
Interleukin-11 Signaling Pathway | 43 | 43 | NaN |
Gastric acid production | 1 | 1 | NaN |
Alpha 6 Beta 4 signaling pathway | 33 | 33 | NaN |
Acetylcholine Synthesis | 5 | 5 | NaN |
Oxytocin signaling | 4 | 4 | NaN |
TCA Cycle | 17 | 17 | NaN |
Neurotransmitter Clearance In The Synaptic Cleft | 4 | 4 | NaN |
Gastric cancer network 2 | 30 | 30 | NaN |
Proteasome Degradation | 60 | 60 | NaN |
TarBasePathway | 12 | 12 | NaN |
ATM Signaling Pathway | 41 | 41 | NaN |
Cytokines and Inflammatory Response | 16 | 16 | NaN |
Type III interferon signaling | 7 | 7 | NaN |
Sphingolipid Metabolism | 20 | 20 | NaN |
Mesodermal Commitment Pathway | 67 | 67 | NaN |
Translation Factors | 50 | 50 | NaN |
Physiological and Pathological Hypertrophy of the Heart | 23 | 23 | NaN |
Cholesterol Biosynthesis | 15 | 15 | NaN |
Primary Focal Segmental Glomerulosclerosis FSGS | 69 | 69 | NaN |
Effects of Nitric Oxide | 6 | 6 | NaN |
Cardiac Hypertrophic Response | 53 | 53 | NaN |
Homologous recombination | 13 | 13 | NaN |
Heme Biosynthesis | 9 | 9 | NaN |
Eicosanoid Synthesis | 18 | 18 | NaN |
NLR Proteins | 8 | 8 | NaN |
Nucleotide Metabolism | 19 | 19 | NaN |
Glucuronidation | 11 | 11 | NaN |
SIDS Susceptibility Pathways | 144 | 144 | NaN |
Gastric Cancer Network 1 | 28 | 28 | NaN |
BDNF signaling pathway | 142 | 142 | NaN |
Regulation of Actin Cytoskeleton | 139 | 139 | NaN |
Apoptosis | 81 | 81 | NaN |
TGF beta Signaling Pathway | 129 | 129 | NaN |
IL-9 Signaling Pathway | 15 | 15 | NaN |
Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | 20 | 20 | NaN |
IL-2 Signaling Pathway | 40 | 40 | NaN |
Estrogen Receptor Pathway | 12 | 12 | NaN |
miRNA Biogenesis | 6 | 6 | NaN |
Glial Cell Differentiation | 7 | 7 | NaN |
Pilocytic astrocytoma | 4 | 4 | NaN |
Notch Signaling Pathway | 58 | 58 | NaN |
RANKL/RANK Signaling Pathway | 54 | 54 | NaN |
Allograft Rejection | 56 | 56 | NaN |
Cell Cycle | 101 | 101 | NaN |
Structural Pathway of Interleukin 1 (IL-1) | 48 | 48 | NaN |
Osteopontin Signaling | 12 | 12 | NaN |
Wnt Signaling Pathway Netpath | 50 | 50 | NaN |
Aryl Hydrocarbon Receptor Pathway | 36 | 36 | NaN |
Endochondral Ossification | 57 | 57 | NaN |
Steroid Biosynthesis | 8 | 8 | NaN |
Neural Crest Differentiation | 91 | 91 | NaN |
Ovarian Infertility Genes | 31 | 31 | NaN |
ID signaling pathway | 15 | 15 | NaN |
Estrogen metabolism | 15 | 15 | NaN |
Arachidonate Epoxygenase / Epoxide Hydrolase | 6 | 6 | NaN |
Serotonin Receptor 4/6/7 and NR3C Signaling | 17 | 17 | NaN |
Glycerophospholipid Biosynthetic Pathway | 21 | 21 | NaN |
ACE Inhibitor Pathway | 10 | 10 | NaN |
Butyrate-induced histone acetylation | 2 | 2 | NaN |
Synthesis and Degradation of Ketone Bodies | 4 | 4 | NaN |
One carbon donor | 1 | 1 | NaN |
Vitamin D Metabolism | 9 | 9 | NaN |
Thyroxine (Thyroid Hormone) Production | 4 | 4 | NaN |
G13 Signaling Pathway | 36 | 36 | NaN |
GPCRs, Class B Secretin-like | 19 | 19 | NaN |
DNA Replication | 42 | 42 | NaN |
Drug Induction of Bile Acid Pathway | 12 | 12 | NaN |
Fatty Acid Omega Oxidation | 11 | 11 | NaN |
HIF1A and PPARG regulation of glycolysis | 0 | 0 | NaN |
PCSK9-mediated LDLR degradation | 1 | 1 | NaN |
Histone Modifications | 55 | 55 | NaN |
MAPK Cascade | 29 | 29 | NaN |
Prostaglandin Synthesis and Regulation | 25 | 25 | NaN |
miRNA Regulation of DNA Damage Response | 74 | 74 | NaN |
IL-4 Signaling Pathway | 53 | 53 | NaN |
G Protein Signaling Pathways | 87 | 87 | NaN |
TOR Signaling | 33 | 33 | NaN |
IL-6 signaling pathway | 41 | 41 | NaN |
DNA Damage Response | 68 | 68 | NaN |
MAPK Signaling Pathway | 160 | 160 | NaN |
Hedgehog Signaling Pathway | 15 | 15 | NaN |
Phospholipid biosynthesis | 0 | 0 | NaN |
IL-7 Signaling Pathway | 23 | 23 | NaN |
Dopamine metabolism | 11 | 11 | NaN |
Type II diabetes mellitus | 19 | 19 | NaN |
GPCRs, Class C Metabotropic glutamate, pheromone | 15 | 15 | NaN |
Signaling Pathways in Glioblastoma | 81 | 81 | NaN |
miRNAs involved in DNA damage response | 18 | 18 | NaN |
Farnesoid X Receptor Pathway | 12 | 12 | NaN |
Mismatch repair | 9 | 9 | NaN |
Glycogen Metabolism | 36 | 36 | NaN |
Peptide GPCRs | 43 | 43 | NaN |
Kit receptor signaling pathway | 59 | 59 | NaN |
Liver X Receptor Pathway | 9 | 9 | NaN |
Selenium Metabolism and Selenoproteins | 39 | 39 | NaN |
TNF alpha Signaling Pathway | 88 | 88 | NaN |
Iron metabolism in placenta | 12 | 12 | NaN |
Vitamin A and Carotenoid Metabolism | 37 | 37 | NaN |
Glycine Metabolism | 3 | 3 | NaN |
Fatty Acid Biosynthesis | 22 | 22 | NaN |
Triacylglyceride Synthesis | 19 | 19 | NaN |
Arylamine metabolism | 4 | 4 | NaN |
Monoamine Transport | 25 | 25 | NaN |
Estrogen signaling pathway | 22 | 22 | NaN |
Pathogenic Escherichia coli infection | 52 | 52 | NaN |
Aflatoxin B1 metabolism | 7 | 7 | NaN |
TP53 Network | 21 | 21 | NaN |
Nanoparticle-mediated activation of receptor signaling | 27 | 27 | NaN |
Apoptosis-related network due to altered Notch3 in ovarian cancer | 53 | 53 | NaN |
Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis | 13 | 13 | NaN |
Notch Signaling Pathway | 43 | 43 | NaN |
DNA Damage Response (only ATM dependent) | 109 | 109 | NaN |
Trans-sulfuration and one carbon metabolism | 30 | 30 | NaN |
Sulindac Metabolic Pathway | 5 | 5 | NaN |
Irinotecan Pathway | 12 | 12 | NaN |
Oxidative Stress | 28 | 28 | NaN |
Ganglio Sphingolipid Metabolism | 17 | 17 | NaN |
Differentiation of white and brown adipocyte | 23 | 23 | NaN |
Senescence and Autophagy in Cancer | 99 | 99 | NaN |
Iron uptake and transport | 99 | 99 | NaN |
Glycolysis and Gluconeogenesis | 43 | 43 | NaN |
Nuclear Receptors in Lipid Metabolism and Toxicity | 25 | 25 | NaN |
Mitochondrial Gene Expression | 19 | 19 | NaN |
Arylhydrocarbon receptor (AhR) signaling pathway | 24 | 24 | NaN |
Transcriptional activation by NRF2 | 15 | 15 | NaN |
NAD Biosynthesis II (from tryptophan) | 7 | 7 | NaN |
Biogenic Amine Synthesis | 10 | 10 | NaN |
BMP Signalling and Regulation | 12 | 12 | NaN |
Osteoclast Signaling | 14 | 14 | NaN |
Toll-like receptor signaling pathway | 81 | 81 | NaN |
Non-homologous end joining | 8 | 8 | NaN |
Retinoblastoma (RB) in Cancer | 88 | 88 | NaN |
Sulfation Biotransformation Reaction | 15 | 15 | NaN |
Aryl Hydrocarbon Receptor | 45 | 45 | NaN |
FAS pathway and Stress induction of HSP regulation | 41 | 41 | NaN |
Signal Transduction of S1P Receptor | 25 | 25 | NaN |
Regulation of Microtubule Cytoskeleton | 44 | 44 | NaN |
Cytoplasmic Ribosomal Proteins | 87 | 87 | NaN |
Ectoderm Differentiation | 134 | 134 | NaN |
Signaling of Hepatocyte Growth Factor Receptor | 34 | 34 | NaN |
Corticotropin-releasing hormone | 86 | 86 | NaN |
SREBF and miR33 in cholesterol and lipid homeostasis | 16 | 16 | NaN |
IL-5 Signaling Pathway | 38 | 38 | NaN |
Leptin signaling pathway | 75 | 75 | NaN |
TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer | 5 | 5 | NaN |
MicroRNAs in cardiomyocyte hypertrophy | 80 | 80 | NaN |
Metastatic brain tumor | 7 | 7 | NaN |
Phase I biotransformations, non P450 | 7 | 7 | NaN |
Lidocaine metabolism | 2 | 2 | NaN |
GPCRs, Class A Rhodopsin-like | 137 | 137 | NaN |
Peroxisomal beta-oxidation of tetracosanoyl-CoA | 4 | 4 | NaN |
Fatty Acid Beta Oxidation | 31 | 31 | NaN |
One Carbon Metabolism | 26 | 26 | NaN |
Amino acid conjugation | 0 | 0 | NaN |
miRNA targets in ECM and membrane receptors | 22 | 22 | NaN |
Integrin-mediated Cell Adhesion | 96 | 96 | NaN |
Apoptosis Modulation and Signaling | 86 | 86 | NaN |
Dopaminergic Neurogenesis | 23 | 23 | NaN |
IL-3 Signaling Pathway | 44 | 44 | NaN |
Nicotine Activity on Chromaffin Cells | 4 | 4 | NaN |
Neurotransmitter Release Cycle | 13 | 13 | NaN |
Nuclear Receptors | 36 | 36 | NaN |
NRF2 pathway | 121 | 121 | NaN |
TCR Signaling Pathway | 79 | 79 | NaN |
Tryptophan metabolism | 39 | 39 | NaN |
SRF and miRs in Smooth Muscle Differentiation and Proliferation | 11 | 11 | NaN |
Apoptosis Modulation by HSP70 | 19 | 19 | NaN |
SREBP signalling | 64 | 64 | NaN |
Influenza A virus infection | 1 | 1 | NaN |
Inflammatory Response Pathway | 19 | 19 | NaN |
Endothelin Pathways | 26 | 26 | NaN |
Amyotrophic lateral sclerosis (ALS) | 36 | 36 | NaN |
Felbamate Metabolism | 2 | 2 | NaN |
NOD pathway | 37 | 37 | NaN |
Type II interferon signaling (IFNG) | 30 | 30 | NaN |
Serotonin Receptor 2 and STAT3 Signaling | 4 | 4 | NaN |
Nicotine Activity on Dopaminergic Neurons | 17 | 17 | NaN |
Electron Transport Chain | 89 | 89 | NaN |
Colchicine Metabolic Pathway | 1 | 1 | NaN |
Hypertrophy Model | 18 | 18 | NaN |
Endoderm Differentiation | 63 | 63 | NaN |
Folate-Alcohol and Cancer Pathway | 8 | 8 | NaN |
Benzo(a)pyrene metabolism | 8 | 8 | NaN |
Glucocorticoid & Mineralcorticoid Metabolism | 6 | 6 | NaN |
Oncostatin M Signaling Pathway | 61 | 61 | NaN |
Polyol Pathway | 3 | 3 | NaN |
PPAR Alpha Pathway | 20 | 20 | NaN |
Diclofenac Metabolic Pathway | 4 | 4 | NaN |
Striated Muscle Contraction | 31 | 31 | NaN |
Androgen receptor signaling pathway | 87 | 87 | NaN |
Integrated Breast Cancer Pathway | 159 | 159 | NaN |
Matrix Metalloproteinases | 19 | 19 | NaN |
Metapathway biotransformation | 137 | 137 | NaN |
miRs in Muscle Cell Differentiation | 25 | 25 | NaN |